Clinical Trial: Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therap

Brief Summary:

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

Detailed Summary: For additional information please call: 1-800-718-1021
Sponsor: Pfizer

Current Primary Outcome: Change in LDL-C and non-HDL-C levels.

Original Primary Outcome: Same as current

Current Secondary Outcome: Changes in other lipid and biomarker variable levels.

Original Secondary Outcome: Same as current

Information By: Pfizer

Dates:
Date Received: August 31, 2005
Date Started: March 2005
Date Completion:
Last Updated: February 15, 2012
Last Verified: February 2012